Avantor, Inc. (NYSE:AVTR) Receives $12.47 Average PT from Analysts

Avantor, Inc. (NYSE:AVTR) has received an average rating of “Hold” from the eighteen ratings firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, fifteen have given a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $12.4706.

Several research analysts have weighed in on the company. Royal Bank Of Canada increased their price objective on Avantor from $9.00 to $14.00 and gave the stock a “sector perform” rating in a research report on Thursday, July 30th. Wolfe Research upgraded shares of Avantor from a “strong sell” rating to a “hold” rating in a research note on Thursday, July 30th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $13.00 price target on shares of Avantor in a research report on Thursday, July 30th. Citigroup lifted their price objective on shares of Avantor from $9.00 to $11.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 8th. Finally, Sanford C. Bernstein initiated coverage on shares of Avantor in a research report on Friday, June 26th. They set a “market perform” rating and a $10.50 target price on the stock.

Institutional Investors Weigh In On Avantor

A number of large investors have recently added to or reduced their stakes in AVTR. Sequoia Financial Advisors LLC grew its stake in Avantor by 100.1% during the second quarter. Sequoia Financial Advisors LLC now owns 22,739 shares of the company’s stock worth $225,000 after buying an additional 11,378 shares in the last quarter. Engineers Gate Manager LP lifted its holdings in shares of Avantor by 362.5% during the 2nd quarter. Engineers Gate Manager LP now owns 54,570 shares of the company’s stock worth $540,000 after acquiring an additional 42,770 shares during the period. Cidel Asset Management Inc. acquired a new stake in shares of Avantor during the 2nd quarter worth approximately $112,000. Integrated Wealth Concepts LLC acquired a new stake in shares of Avantor during the 2nd quarter worth approximately $128,000. Finally, IFP Advisors Inc increased its stake in Avantor by 901.4% in the second quarter. IFP Advisors Inc now owns 5,858 shares of the company’s stock valued at $58,000 after acquiring an additional 5,273 shares during the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Avantor Price Performance

Avantor stock opened at $15.15 on Friday. Avantor has a 12 month low of $7.26 and a 12 month high of $15.93. The stock’s 50 day moving average is $13.20 and its 200-day moving average is $10.19. The company has a current ratio of 1.78, a quick ratio of 1.18 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $10.25 billion, a price-to-earnings ratio of -18.04, a PEG ratio of 11.18 and a beta of 0.89.

Avantor (NYSE:AVTR) last released its quarterly earnings results on Wednesday, July 29th. The company reported $0.21 earnings per share for the quarter, topping the consensus estimate of $0.19 by $0.02. The business had revenue of $1.69 billion during the quarter, compared to analysts’ expectations of $1.61 billion. Avantor had a positive return on equity of 9.92% and a negative net margin of 8.81%.The firm’s revenue for the quarter was up .5% compared to the same quarter last year. During the same period last year, the firm posted $0.24 EPS. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. Equities research analysts expect that Avantor will post 0.81 EPS for the current year.

About Avantor

Avantor, Inc (NYSE: AVTR) is a global provider of products and services used in the life sciences, healthcare and advanced technology industries. The company supports research, drug discovery, biopharmaceutical production, clinical and diagnostic activities, and other laboratory-based applications.

Its offerings include laboratory chemicals and reagents, consumables, equipment, instruments, production materials and related services. Avantor also provides supply-chain, procurement and other technical solutions designed to help customers manage laboratory and manufacturing operations.

Avantor serves customers across pharmaceutical and biopharmaceutical companies, healthcare providers, academic and government institutions, medical laboratories and industrial businesses.